Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13918235 | 0.88 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL20621524 | 0.86 | TSHR (0.33) | — | |
| SCHEMBL1470454 | 0.84 | — | — | |
| SCHEMBL9336747 | 0.78 | — | — | |
| SCHEMBL9533687 | 0.77 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL617542 | 0.77 | — | — | |
| SCHEMBL10782199 | 0.76 | KDM4E (0.33) | — | |
| SCHEMBL3096236 | 0.76 | GAA (0.30) | — | |
| SCHEMBL3129270 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL9837966 | 0.75 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | OXTR, C3AR1, CBR3 | NPC1 2660/4885RAB9A 596/4885SMN1; SMN2 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.